Hardman & Co Q&A with Dr Martin Hall: Avacta Group Plc (LON:AVCT)
12th December 2018
Hardman and Co’s Dr Martin Hall discusses Avacta Group Plc in this exclusive interview with DirectorsTalk.
Hardman and Co’s Dr Martin Hall discusses Avacta Group Plc in this exclusive interview with DirectorsTalk.
Avacta Group plc (LON: AVCT) is the topic of conversation when Dr Martin Hall, Head of Life Sciences from Hardman & Co joins DirectorsTalk. Martin firstly explains what ‘Affimers’ are,
Alastair Smith, Chief Executive of Avacta Group commented: “I am delighted to be entering into this therapeutic development partnership with LG Chem which is a strong validation of the potential
Avacta Group Plc (LON: AVCT) is a pre-clinical stage biotechnology company and the proprietary owner of Affimer technology. Affimers represent a radical alternative to the established antibody technology. The significant
Avacta Plc (LON:AVCT) is a pre-clinical biotechnology company and the proprietary owner of Affimer technology. Affimers represent a radical alternative to the established antibody technology, which continues to dominate the
Avacta Group Plc (LON:AVCT) is the proprietary owner of Affimer technology for the development of bio-therapeutics, diagnostic tests and research reagents. Affimers represent a radical alternative to established antibody technology
Avacta Group Plc (LON:AVCT) is the proprietary owner of Affimer technology for the development of bio-therapeutics, diagnostic tests and research reagents. Affimers represent a radical alternative to established antibody technology
Avacta Group Plc (LON:AVCT) is the proprietary owner of Affimer technology for the development of bio-therapeutics, diagnostic tests and research reagents. Affimers represent a radical alternative to established antibody technology
Avacta Group Plc (LON:AVCT) is the proprietary owner of Affimer technology for the development of bio-therapeutics, diagnostic tests and research reagents. Affimers represent a radical alternative to established antibody technology
Avacta Group Plc (LON:AVCT) is the proprietary owner of Affimer technology for the development of bio-therapeutics, diagnostic tests and research reagents. Affimers represent a radical alternative to established antibody technology
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
